Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 1.00 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 1.00 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 1.00 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | GAPDH | P04406 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL12352425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL1821276 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL4522263 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL24538665 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2228590 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23804425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL406207 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23420216 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2403819 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL19107495 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753433-B2 | Methods of synthesizing substituted purine compounds | Epizyme, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230265123-A1 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | PEPTINOVO BIOPHARMA INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265123-A1 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | PEPTINOVO BIOPHARMA INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2022035818-A2 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | PEPTINOVO BIOPHARMA, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20210363171-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2021-11-25 | — | — | US | disclosed |
| EP-3319980-B1 | FORMULATIONS FOR IMPROVING THE EFFICACY OF HYDROPHOBIC DRUGS | PEPTINOVO BIOPHARMA LLC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10968247-B2 | Methods of synthesizing substituted purine compounds | Epizyme, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-14 | — | — | US | disclosed |
| WO-2020055753-A1 | FLUORESCENT SUBSTRATES FOR POLY(ADP-RIBOSYL) HYDROLASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-03-19 | — | — | WO | disclosed |
| US-20190300562-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | disclosed |
| US-9738679-B2 | Methods of synthesizing substituted purine compounds | Epizyme, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| WO-2017011312-A1 | FORMULATIONS FOR IMPROVING THE EFFICACY OF HYDROPHOBIC DRUGS | PEPTINOVO BIOPHARMA, LLC (US) | 2017-01-19 | — | — | WO | disclosed |
| WO-2014152566-A2 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2009154828-A9 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009154828-A2 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300562-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | DOT1L, MECP2, TDP1 | ADORA3 290/4885ADORA2A 210/4885ADORA2B 456/4885 |
| US-20210363171-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | DOT1L, MECP2, TDP1 | ADORA3 290/4885ADORA2A 210/4885ADORA2B 456/4885 |
| US-10968247-B2 | Methods of synthesizing substituted purine compounds | DOT1L, MECP2, TDP1 | ADORA3 290/4885ADORA2A 210/4885ADORA2B 456/4885 |
| US-20230265123-A1 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | PHOSPHO1, NGLY1, ANXA11 | ADORA3 4466/4885ADORA2A 4756/4885ADORA2B 4735/4885 |
| US-11753433-B2 | Methods of synthesizing substituted purine compounds | DOT1L, MECP2, TDP1 | ADORA3 290/4885ADORA2A 210/4885ADORA2B 456/4885 |
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA3 275/4885ADORA2A 102/4885ADORA2B 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.